Einfluss thrombophiler Faktoren bei Patientinnen mit wiederholtem Spontanabort

L. Heilmann

doi:10.1055/s-0037-1619672

Hämostaseologie, Table of Contents

Hamostaseologie 2005; 25(04): 387-390
DOI: 10.1055/s-0037-1619672

Original Article

Schattauer GmbH

Einfluss thrombophiler Faktoren bei Patientinnen mit wiederholtem Spontanabort

Pro und KontraInfluence of thrombophilia in women with recurrent miscarriage: pros and cons

L. Heilmann

¹Klinik für Geburtshilfe und Frauenkrankheiten, GPR Klinikum Rüsselsheim

› Author Affiliations

Abstract

Zusammenfassung

Der wiederholte Spontanabort (WSA) ist eine inhomogene und multifaktoriell bedingte Krankheitsgruppe, die bei ca. 5% der Schwangerschaften auftritt. Die Thrombophilie (erworben und angeboren) ist in 50 bis 60% der Fälle mit dem Abortgeschehen verbunden. Die Therapie einer Thrombophilie mit niedermolekularem Heparin bei Frauen mit WSA wird kontrovers diskutiert, obwohl die Sicherheit der niedermolekularen Heparine mittlerweile unbestritten ist. Einige Fall-Kontroll-Studien und eine prospektive Studie haben einen eindeutigen Effekt der niedermolekularen Heparine mit einer statistisch signifikanten Verminderung der Abortrate erbracht.

Summary

Recurrent miscarriage is a heterogeneous condition. A large number of studies have suggested a significant role for inherited and acquired thrombophilia in the development of abortion. Preliminary case-control studies and one prospective trial suggest that low molecular weight heparin is effective in preventing pregnancy loss in women with thrombophilia and previous recurrent miscarriage.

Schlüsselwörter

Spontanabort - Thrombophilie - niedermolekulares Heparin

Keywords

Recurrent spontaneous abortion - thrombophilie - low molecular weight heparin

Full Text

References

Literatur
1 Backos M, Rai R, Baxter N. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. BJOG 1999; 106: 102-7.
2 Bar J, Lahav J, Kapustian V. et al. Effect of thrombophylaxis on pregnancy outcome in women with thrombophilia. Arch Perinat Med 1999; 1: 35-7.
3 Bar J, Cohen-Sacher B, Hod M. Low-molecularweight heparin for thrombophilia in pregnant women. Int J Gynaecol Obstet 2000; 69: 209-13.
4 Branch DW, Silver LM, Blackwell JL. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992; 80: 614-20.
5 Branch DW, Pearceman AM, Druzin M. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 2000; 182: 122-7.
6 Branch DW, Flint Porter T, Paiodas MJ. et al. Obstetric uses of intravenous immunoglobulin: Successes, failures, and promises. J Allergy Clin Immunol 2001; 108: 133-8.
7 Brenner B, Nowak-Göttl U, Kosch A. et al. Diagnostic studies for thrombophilia in women on hormonal therapy and during pregnancy, and children. Arch Pathol Lab Med 2002; 126: 1296-303.
8 Brenner B. Enoxaparin reduces pregnancy loss in women with thrombophilia. Annual Meeting of the American Society of Haematology. 2003. San Diego.:
9 Brenner B. Maternal anticoagulant prophylaxis for prevention of pregnancy loss in women with thrombophilia. J Thromb Haemost 2003; 1: 416-7.
10 Brenner B. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications – Yes. J Thromb Haemost 2003; 1: 2070-2.
11 Brenner B. Clinical management of thrombophilia-related placental vascular complications. Blood 2004; 103: 4003-9.
12 Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Throm Haemost 2002; 1: 433-8.
13 Dudding TE, Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis. Thromb Haemost 2004; 91: 700-11.
14 Empson M, Lassere M, Craig JC. et al. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 2002; 99: 135-44.
15 Grandone E, Brancaccio V, Colaizzo BS. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril 2002; 78: 371-5.
16 Granger KA, Farquharson RG. Obstetric outcome in antiphospholipid syndrome. Lupus 1997; 6: 509-13.
17 Gris J-Ch, Mercier E, Quere I. et al. Low molecular weight heparin versus low dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 3695-9.
18 Heilmann L, GF v Tempelhoff GF, Pollow K. The influence of antiphospholipid antibodies on the pregnancy outcome of patients with recurrent spontaneous abortion. Clin Appl Thromb/Hemost 2001; 7: 281-5.
19 Heilmann L, Rath W. Thombophilie in der Schwangerschaft. Unimed; 2002
20 Heilmann L, v Tempelhoff GF Pollow K. Antiphospholipid Syndrome in Obstetrics. Clin Appl Thromb/Hemost 2003; 9: 143-50.
21 Heilmann L, Mallmann P, Thaler CHJ. et al. AG Immunologie in Gynäkologie und Geburtshilfe der DGGG. Empfehlungen zur Diagnostik und Therapie des wiederholten Spontanabortes (WSA). Frauenarzt. (im Druck).
22 Khare M, Nelson-Piercy C. Acquired thrombophilia and pregnancy. Best Practice Res Clin Obstet Gynaecol 2003; 17: 491-507.
23 Knudsen UB, Hansen V, June S. et al. Prognosis of a new pregnancy following previous spontaneous abortion. Eur J Obstet Gynecol Biol 1991; 39: 31-6.
24 Kovalevsky G, Gracia CR, Berlin JA. et al. Evaluation of the association between hereditary thrombophilia and recurrent pregnancy loss. A Meta-analysis. Arch Intern Med 2004; 164: 558-63.
25 Krabbendam I, Dekker GA. Pregnancy outcome in patients with a history of recurrent spontaneous miscarriage and documented thrombophilias. Gynecol Obstet Invest 2004; 57: 127-31.
26 Kupferminc MJ, Fait G, Many A. Low molecular weight heparin for prevention of obstetric complications in women with thrombophilia. Hypertens Pregnancy 2001; 20: 35-44.
27 Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low dose aspirin is superior to low dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-9.
28 Kutteh WH. Antiphospholipid antibodies and reproduction. J Reprod Immunol 1997; 35: 151-71.
29 Li TC, Makris M, Tomsu M. et al. Recurrent miscarriage: aetiology, management and prognosis. Human Reprod Update 2002; 8: 463-81.
30 Lima F, Khamasthta MA, Buchanan NM. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exper Rheumatol 1996; 14: 131-6.
31 McLintock C, North RA, Dekker GA. Inherited thrombophilia: Implications for pregnancy-associated venous thromboembolism and obstetric complications. Curr Probl Obstet Gynecol Fertil 2001; 24: 115-49.
32 Menge S, Müller-Lantzsch C, Keck C. et al. Habituelle Aborte – ein aktueller Überblick über Ursachen und therapeutische Möglichkeiten. Geburtsh Frauenheil 2004; 64: 574-83.
33 Middeldorp S. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications – No. J Thromb Haemost 2003; 1: 2073-4.
34 Preston FE, Rosendaal FR, Walker ID. et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-6.
35 Rai RS, Cohen H, Clifford K. et al. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Human Reprod 1995; 10: 3301-4.
36 Rai R, Cohen H, Dave M. et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997; 314: 253-7.
37 Rai R, Backos M, Baxter N. et al. Recurrent miscarriage-an aspirin a day. Human Reprod 2000; 15: 2220-3.
38 Rey E, Kahn SR, David M. et al. Thrombophilic disorders and fetal loss: a metaanalysis. Lancet 2003; 361: 901-8.
39 Riyazi N, Leeda M, de Vries JL. Low molecular weight heparin combined with aspirin in pregnant women with thrombophilia and history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol 1998; 80: 49-54.
40 Roque H, Paidar MJ, Funai EF. et al. Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost 2004; 91: 290-5.
41 Sarig G, Younis JS, Hoffman R. et al. Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril 2002; 77: 342-7.
42 Scott JR, Branch WD. Immunology of early pregnancy loss. Contemporary Ob/Gyn 1998; 43: 40-56.
43 Vanitier D, Dufour P, Cosson M. et al. Antiphospholipid syndrome and recurrent miscarriages. Europe J Obstet Gynecol Reprod Biol 2001; 96: 37-50.
44 Vossen CY, Preston FE, Conard J. et al. Hereditary thrombophilia and fetal loss: a prospective followup study. J Thromb Haemost 2004; 2: 592-6.
45 Younis JS, Ohel G, Brenner B. The effect of thromboprophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. BJOG 2000; 107: 415-9.